Back to search results

Telemedicine-Delivered Therapy for PTSD in Opioid Use Disorder

This study is testing a new way to deliver prolonged exposure therapy (a type of talk therapy for trauma) using telemedicine (therapy sessions over video or phone) for people who have both opioid use disorder (OUD) and posttraumatic stress disorder (PTSD). We know that PTSD is very common in people with OUD, and it can make recovery harder. This study wants to see if offering therapy this way, sometimes with financial incentives, can help more people attend sessions and reduce their PTSD symptoms. You might be able to join if you are over 18, are on a stable dose of methadone or buprenorphine for OUD, and meet the criteria for PTSD. The study aims to enroll 135 participants. The current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 135 participants.
What's involved
Participants will either continue their usual buprenorphine or methadone treatment, or receive twelve weekly 60-minute telemedicine-delivered prolonged exposure therapy sessions, potentially with financial incentives.
Compensation
Financial incentives are offered for completing prolonged exposure therapy sessions.
Follow-up
PTSD symptoms will be measured from the start of the study to week 12, and at 3- and 6-months after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06288711

Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD

Recruiting
NAAges 18+InterventionalTreatment
University of Vermont
~135 participants
Updated 2026-05-18 on ClinicalTrials.gov
What's tested:Prolonged exposure therapyFinancial incentivesTreatment as usual

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prolonged exposure therapy session attendance
Measured over From baseline to week 12
+2 more outcomes measured

Conditions

Opioid Use Disorder
Posttraumatic Stress Disorder

Explore related trials

Opioid Use DisorderPost-Traumatic Stress Disorder

Where it's being run

1 sites across 1 states
Vermont1

Who to contact

Kelly Peck, Ph.D.
[email protected]
8026569610
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\>18 years old
Maintained on a stable methadone or buprenorphine dose for \>1 month prior to the study
Meet current DSM-5 posttraumatic stress disorder criteria based on the Clinician Administered PTSD Scale for DSM-5
Participants receiving psychotropic medications must be maintained on a stable dose for \>1 month prior to enrollment.

Exclusion

Current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the Mini International Neuropsychiatric Interview
Cognitive impairment as evidenced by scores \<22 on the Videoconference-based Mini Mental Status Examination (MMSE; Folstein, et al., 1975)
Enrolled in another ongoing evidence-based treatment for PTSD.
Pregnancy as verified by pregnancy test
No access to cellular service

What this trial measures

  • Prolonged exposure therapy session attendanceFrom baseline to week 12

    Percentage of scheduled prolonged exposure therapy sessions attended

  • Prolonged exposure therapy completionFrom baseline to week 12

    Percentage of participants completing eight or more prolonged exposure therapy sessions

  • Change in posttraumatic stress disorder symptom severity - clinician ratedFrom baseline to week 12

    Change in posttraumatic stress disorder symptom severity as measured by Clinician Administered PTSD Scale (CAPS-5) for clinician-rated posttraumatic stress symptoms. The CAPS-5 is a 30-item structured interview. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 PTSD symptoms, each with severity scores ranging from 0-4. The overall total severity score for CAPS-5 ranges from 0-80, with lower scores representing better outcomes (less severe PTSD).